Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). - Dang,C.T.; Lin,N.U.; Lake,D.; Dickler,M.N.; Modi,S.; Seidman,A.D.; Steingart,R.M.; Norton,L.; Winer,E.P.; Hudis,C.A. (J Clin Oncol, 2008)